EQS-News: BioCorRx Inc
/ Key word(s): Financial
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales 14.08.2025 / 20:30 CET/CEST
The issuer is solely responsible for the content of…Read More
You might also be interested in reading Bybit Slashes Stock CFD Costs to Zero, Turning Up Pressure on Retail CFD Brokers.